Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
7.80
-0.01 (-0.13%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.

The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.

The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial.

The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.

Immatics N.V. is headquartered in Tübingen, Germany.

Immatics N.V.
Immatics logo
Country Germany
Industry Biotechnology
Sector Healthcare
Employees 535
CEO Harpreet Singh

Contact Details

Address:
Paul-Ehrlich-Strasse 15
Tübingen, 72076
Germany
Phone 49 7071 5397 0
Website immatics.com

Stock Details

Ticker Symbol IMTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
CIK Code 0001809196
CUSIP Number N44445109
ISIN Number NL0015285941
SIC Code 2836

Key Executives

Name Position
Dr. Harpreet Singh Ph.D. Chief Executive Officer, MD, Member of Management Board and Executive Director
Dr. Toni Weinschenk Ph.D. Co-Founder and Chief Innovation Officer
Arnd Christ MBA Chief Financial Officer
Steffen Walter Ph.D. Chief Operations Officer
Edward A. Sturchio General Counsel and Secretary
Dr. Carsten Reinhardt M.D., Ph.D. Chief Development Officer
Cedrik M. Britten M.D. Chief Medical Officer
Jordan Silverstein Head of Strategy
Dr. Hans-Georg Rammensee Ph.D. Co-Founder and Member of the Scientific Advisory Board
Ephraim Hofsäß M.Sc. Vice President of SEC Reporting and Accounting

Latest SEC Filings

Date Type Title
Nov 18, 2024 6-K Report of foreign issuer
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 6-K Report of foreign issuer
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 17, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 15, 2024 6-K Report of foreign issuer
Oct 11, 2024 424B2 Prospectus
Oct 10, 2024 424B2 Prospectus
Oct 10, 2024 F-3ASR Filing